Quantel Medical today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on March 02, 2018 for the Next-Generation Compact Touch Ophthalmic Ultrasound Platform.
Since the first generation of Compact Touch was launched in 2008, more than 3,300 units have been sold worldwide. This best-selling Quantel Medical ultrasound product has been prized for its high image quality, intuitive software, compact design and versatility.
Improvements in the new generation of Compact Touch include a new 15 MHz B probe to increase the quality of the B-scan imaging essential to vitreo-retinal specialists. Interactivity is enhanced with DICOM compatibility, WiFi and Bluetooth connectivity and HDMI video output. The sleek, modern design now utilizes a new generation touch screen interface, and the device is fanless and silent as a tablet. User-friendly design and software enhancements improve workflow.
The new generation 15 MHz B probe of the Compact Touch offers a resolution increased by 30%, which enables me to better differentiate thin vitreous membranes and retinal detachments. It also allows me to visualize tumors inferior to 2mm. In addition, the system automatically measures the axial length from the B-mode image, which is advantageous when I am evaluating patients who have long myopic eyes, such as patients with staphylomas.
Dr. Bievelez – Paufique ophthalmologic center, Lyon, France
At the upcoming ASCRS Congress, to be held in Washington April 13-17, the attendees will have the possibility to get a full review of the new generation of the Compact Touch ultrasound platform with its new B-mode probe and get additional information in exhibit booth #850.
For more information about Compact Touch®, visit our website for healthcare professionnals: